MaaT Pharma SA (4RD.F)
| Previous Close | 8.86 |
| Open | 8.10 |
| Bid | 8.78 x N/A |
| Ask | 9.72 x N/A |
| Day's Range | 8.10 - 8.78 |
| 52 Week Range | 4.78 - 9.22 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 106.012M |
| Beta (5Y Monthly) | 0.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.70 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireMaaT Pharma to Hold Annual General Meeting on May 28, 2024
LYON, France, April 22, 2024--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, informs its shareholders that the Annual General Meeting (ordinary and extraordinary) will be held on May, 28, 2024, at 11:00 a.m. CET at the Company’s headquarter in France located at 70 avenue Tony Garnier, 69007 Lyon.
Business WireMaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event
LYON, France, April 15, 2024--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer, presents a summary of its oral presentation at the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) currently being hosted in Glasgow, Scotland from 14-17 April 2024. The presentation is scheduled f
Business WireMaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
LYON, France, April 09, 2024--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, today published the number of shares comprising the share capital and the total number of voting rights (Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité d
